AVBP vs PFE
AVBP: Arrivent Biopharma is a clinical-stage oncology company dedicated to advancing a pipeline of innovative cancer therapies through global development and strategic in-licensing. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | AVBP | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $18.85 | $30.11 | |
| Market cap | $929M | $171.6B | |
| P/E as of 2026-10-20 | n/a | 39.62 | |
| Net margin FY2025, SEC XBRL | n/a | +12.4% | |
| ROE FY2025, SEC XBRL | -54.1% | +9.0% | PFE higher |
| ROA FY2025, SEC XBRL | -49.9% | +3.7% | PFE higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-28 | n/a | 0.74 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -1.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.97 | 0.38 | |
| 1-year return as of 2026-10-20 close | -5.7% | +22.0% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.